RPG Life Sciences delivered robust FY26 results, with revenue growing 8.3% YoY to ₹707.5 Cr.

Domestic Formulations, contributing 69% of sales, was a key performer, growing 1.6x faster than the Indian Pharma Market and ranking as the 4th fastest-growing company in IPM during Q4. Strong profitability led to an EBITDA of ₹172.7 Cr (24.4% margin) and an EPS of ₹69.6. ROCE stood at 28.5% and ROE at 21.1%. Strategic focus areas include deepening presence in high-growth therapies like nephrology, rheumatology, and oncology, alongside successful new product launches.

The company is enhancing manufacturing capabilities through focused capex (over ₹185 Cr invested in 5 years) and driving efficiency with digital tools.

Looking ahead, management aims to build mega brands, grow API and International Formulations in new markets, and pursue strategic acquisitions and R&D for future expansion.

ESG initiatives and continuous cost optimization remain key priorities.